<DOC>
	<DOCNO>NCT01312493</DOCNO>
	<brief_summary>This non-randomized phase II study target radiotherapy ( RT ) administer concurrently panitumumab patient locally advance squamous carcinoma head neck .</brief_summary>
	<brief_title>Selective IMRT Locally Advanced Head Neck Carcinoma With Concurrent Panitumumab</brief_title>
	<detailed_description>This non-randomized phase II trial target radiotherapy ( RT ) administer concurrently panitumumab patient locally advance squamous cell carcinoma head neck . This protocol address patient medical comorbidities make poor candidate concurrent chemotherapy . Radiotherapy treatment direct disease visible diagnostic imaging modality ipsilateral hemi-neck , spar elective region contralateral N0 hemi-neck le 20 % chance microscopic involvement . We explore follow hypothesis : Can acceptable locoregional disease control obtain less treatment-related morbidity focus RT region gross disease , spar region low risk harbor subclinical disease elective RT ?</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven primary squamous cell carcinoma arise oral cavity , oropharynx , hypopharynx , larynx . Stage III , IVA , IVB disease ( locally advance systemic metastasis without bilateral nodal disease , i.e. , N2c ) . Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤2 life expectancy &gt; 12 month . Patients eligible concurrent medical condition render poor candidate chemotherapy . Patients consider group follow criterion meet : Serum creatinine &gt; 1.5 mg/dl ( estimate creatinine clearance &lt; 50mL/min ) ; Insulin dependent diabetes ; SGOT , SGPT , alkaline phosphatase &gt; 2.5 x upper limit normal ; History significant CAD ( myocardial infarction [ MI ] , coronary artery bypass graft [ CABG ] , coronary stent , symptomatic angina ) ; Congestive heart failure [ CHF ] ( LVEF &lt; 40 % echocardiogram MUGA ) ; nephropathy ; Prior history malignancy treat chemotherapy ; Severe chronic obstructive pulmonary disease [ COPD ] , define FEV1 &lt; 1L ; In opinion treat physician , patient would tolerate administration concurrent chemotherapy radiation Age &gt; 18 year . The patient medically fit tolerate course definitive RT . The patient adequate hematologic function define : absolute neutrophil count &gt; 1000/ml , hematocrit &gt; 24 % , platelet count &gt; 50,000/ml . Patients hematocrit 20 % 24 % undergo transfusion , may enrol provide hematocrit reach &gt; 24 % . The patient may prior malignancy must diseasefree three year prior study entry . A history superficial nonmelanoma skin cancer situ carcinoma cervix less three year allow . The patient must agree use effective contraception childbearing potential exists continue contraception least 6 month follow completion study . Evaluation dental service prior initiation radiation therapy . Patient must inform investigational nature study sign inform consent form . The patient receive radiation therapy previously head neck . NOTE : Previous radiotherapy skin cancer head neck permit field overlap significantly . All gross disease surgically resect . NOTE : Patients excisional neck biopsy eligible . Patient positive contralateral neck node whether ipsilateral neck negative positive . The patient pregnant lactating . Squamous cell carcinoma arise nasopharynx , sinus , salivary gland , primary unknown . Nonsquamous histology ( adenoid cystic mucoepidermoid carcinoma ) . Spindle cell squamous carcinoma mixed carcinoma/sarcoma . Scleroderma active connective tissue disorder ( Lupus ) . Any underlying psychological condition would prohibit understanding rendering informed consent . Major surgery &lt; 3 week prior study entry . History interstitial lung disease , e.g. , pulmonary fibrosis interstitial pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Head neck cancer</keyword>
	<keyword>Phase II</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>Lineberger</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Intensity modulate radiation therapy ( IMRT )</keyword>
	<keyword>Stage III IVB</keyword>
</DOC>